BR112018010669A8 - anticorpo anti-pcsk9 e utilização do mesmo - Google Patents
anticorpo anti-pcsk9 e utilização do mesmoInfo
- Publication number
- BR112018010669A8 BR112018010669A8 BR112018010669A BR112018010669A BR112018010669A8 BR 112018010669 A8 BR112018010669 A8 BR 112018010669A8 BR 112018010669 A BR112018010669 A BR 112018010669A BR 112018010669 A BR112018010669 A BR 112018010669A BR 112018010669 A8 BR112018010669 A8 BR 112018010669A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- functional fragment
- provides
- present
- pcsk9 antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção proporciona um anticorpo ou um fragmento funcional do mesmo que se liga especificamente a pcsk9 com alta afinidade; a presente invenção também proporciona uma molécula de ácido nucleico codificando o anticorpo da invenção ou o fragmento funcional do mesmo, para expressar um vetor de expressão e uma célula hospedeira do anticorpo ou do fragmento funcional do mesmo, e também proporciona um método para produzir o anticorpo ou o fragmento funcional do mesmo. a presente invenção proporciona que o anticorpo ou o fragmento funcional do mesmo é usado para tratar doenças tais como dislipidemia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510846855 | 2015-11-27 | ||
CN201510846855.0 | 2015-11-27 | ||
PCT/CN2016/107042 WO2017088782A1 (zh) | 2015-11-27 | 2016-11-24 | 抗pcsk9抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018010669A2 BR112018010669A2 (pt) | 2018-11-13 |
BR112018010669A8 true BR112018010669A8 (pt) | 2019-02-26 |
Family
ID=58763757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018010669A BR112018010669A8 (pt) | 2015-11-27 | 2016-11-24 | anticorpo anti-pcsk9 e utilização do mesmo |
Country Status (11)
Country | Link |
---|---|
US (1) | US10858447B2 (pt) |
EP (1) | EP3381944A4 (pt) |
JP (2) | JP6738432B2 (pt) |
KR (1) | KR20180085008A (pt) |
CN (2) | CN106810609A (pt) |
BR (1) | BR112018010669A8 (pt) |
MY (1) | MY197221A (pt) |
PH (1) | PH12018501070A1 (pt) |
RU (1) | RU2756012C2 (pt) |
SG (1) | SG11201803898SA (pt) |
WO (1) | WO2017088782A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
CN109963877B (zh) * | 2017-06-14 | 2023-01-20 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
EP3461841B1 (en) | 2017-10-02 | 2019-09-11 | Certest Biotec, S.L. | Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter |
CN111110841A (zh) | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
CN114981288B (zh) * | 2020-07-27 | 2024-05-03 | 深圳华大生命科学研究院 | 一种抗体结合的特征性表位及其应用 |
AR128082A1 (es) * | 2021-12-23 | 2024-03-20 | Novavax Inc | ANTICUERPOS CONTRA LA ESPÍCULA (S) DEL SARS-CoV-2 Y SU USO EN EL TRATAMIENTO DE COVID-19 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101115797B1 (ko) * | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법 |
TW200906439A (en) * | 2007-04-13 | 2009-02-16 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9) |
US7928189B2 (en) * | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
EP2419447B1 (en) * | 2009-04-17 | 2017-08-23 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2442792A4 (en) * | 2009-06-15 | 2015-12-23 | Alnylam Pharmaceuticals Inc | DOUBLE STRANDED RNA IN LIPID FORMULATION TARGETING THE PCSK9 GENE |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
AR087715A1 (es) * | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
CA2875096A1 (en) * | 2012-06-15 | 2013-12-19 | Genentech, Inc. | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
WO2014107739A1 (en) * | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
US20150004174A1 (en) * | 2013-06-28 | 2015-01-01 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
-
2015
- 2015-12-08 CN CN201510895676.6A patent/CN106810609A/zh active Pending
-
2016
- 2016-11-24 BR BR112018010669A patent/BR112018010669A8/pt not_active Application Discontinuation
- 2016-11-24 MY MYPI2018702025A patent/MY197221A/en unknown
- 2016-11-24 US US15/779,438 patent/US10858447B2/en active Active
- 2016-11-24 EP EP16868005.6A patent/EP3381944A4/en active Pending
- 2016-11-24 KR KR1020187017964A patent/KR20180085008A/ko not_active Application Discontinuation
- 2016-11-24 JP JP2018546735A patent/JP6738432B2/ja active Active
- 2016-11-24 SG SG11201803898SA patent/SG11201803898SA/en unknown
- 2016-11-24 WO PCT/CN2016/107042 patent/WO2017088782A1/zh active Application Filing
- 2016-11-24 CN CN201680069565.2A patent/CN109071673B/zh active Active
- 2016-11-24 RU RU2018121413A patent/RU2756012C2/ru active
-
2018
- 2018-05-17 PH PH12018501070A patent/PH12018501070A1/en unknown
-
2020
- 2020-04-23 JP JP2020076919A patent/JP7112659B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP7112659B2 (ja) | 2022-08-04 |
CN109071673A (zh) | 2018-12-21 |
JP2020127411A (ja) | 2020-08-27 |
PH12018501070A1 (en) | 2018-12-17 |
EP3381944A1 (en) | 2018-10-03 |
CN106810609A (zh) | 2017-06-09 |
BR112018010669A2 (pt) | 2018-11-13 |
CN109071673B (zh) | 2021-11-26 |
WO2017088782A1 (zh) | 2017-06-01 |
RU2018121413A3 (pt) | 2020-09-18 |
US20190233540A1 (en) | 2019-08-01 |
RU2018121413A (ru) | 2019-12-30 |
JP2019500411A (ja) | 2019-01-10 |
MY197221A (en) | 2023-06-06 |
RU2756012C2 (ru) | 2021-09-24 |
US10858447B2 (en) | 2020-12-08 |
EP3381944A4 (en) | 2019-08-07 |
JP6738432B2 (ja) | 2020-08-12 |
SG11201803898SA (en) | 2018-07-30 |
KR20180085008A (ko) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018010669A8 (pt) | anticorpo anti-pcsk9 e utilização do mesmo | |
CL2021001179A1 (es) | Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). | |
CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
CO2017005842A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
BR112018007453A2 (pt) | genes modificados de ataxia de friedreich e vetores para a terapia gênica | |
BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
BR112017021021A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
BR112015022462A2 (pt) | inibidores de ido | |
BR112019011582A2 (pt) | anticorpos e métodos de utilização dos mesmos | |
BR112018001531A2 (pt) | construtos de anticorpo para cd70 e cd3 | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112018010673A8 (pt) | moléculas de anticorpo para april e seus usos | |
BR112016021848A2 (pt) | Composições para modulação de expressão de sod-1 | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
BR112015031073A2 (pt) | inibidores bicíclicos de bromodomínio | |
BR112015023262B8 (pt) | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
BR112015032595A2 (pt) | inibidores de ido | |
BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |